How ‘Safe & Effective’ is The New mRNA Influenza Shot?

The newly FDA-approved mRNA influenza vaccine (Moderna’s mRNA-1010, marketed as mFlusiva) for adults aged 50 and older demonstrates superior efficacy over traditional standard-dose flu shots, with a relative vaccine efficacy of 26.6% (95% CI 16.7–35.4) in a large Phase 3 trial involving over 40,000 participants; confirmed influenza-like illness rates were 2.0% versus 2.8%, and the shot’s faster manufacturing timeline may improve strain matching.